ELCC 2021 | Upfront treatment of ROS1-rearranged NSCLC

Federico Cappuzzo • 22 Mar 2021

Lung Cancer Non-Small Cell Lung Cancer Crizotinib Entrectinib Lorlatinib Sunitinib

Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, discusses how to choose the optimal therapy for the upfront treatment of ROS1-rearranged non-small cell lung cancer (NSCLC). Dr Cappuzzo outlines the potential benefits and limitations of crizotinib, entrectinib and lorlatinib for patients with ROS1-rearranged NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.

METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis

Federico Cappuzzo • 7 Aug 2022

Targeting RET in lung cancer

Federico Cappuzzo • 22 Mar 2021

Management of patients with PDL1-high advanced NSCLC

Federico Cappuzzo • 22 Mar 2021

Mechanisms resulting in resistance to checkpoint inhibitors in NSCLC

Federico Cappuzzo • 22 Mar 2022

Related Videos

Building a clinical research platform to capture and leverage data from cancer care in Germany

Frank Griesinger • 6 Dec 2016

ctDNA measurement via liquid biopsy: improving cancer detection and diagnosis

Pierre-Jean Lamy • 26 Nov 2018

How to discuss immunotherapy as a treatment option with lung cancer patients

Rolf Stahel • 29 Jan 2017

Clinical factors in the selection of patients for first-line immunotherapy of lung cancer

Benjamin Besse • 27 Jan 2017